Teriflunomide in relapsing multiple sclerosis: Therapeutic utility

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 5, 2013, Pages 192-205

  Freedman, Mark S ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Disease modifying therapy; Efficacy; Immunomodulator; Relapsing multiple sclerosis; Safety; Teriflunomide

Indexed keywords

ACTIVATED CARBON; BETA INTERFERON; BETA1A INTERFERON; COLESTYRAMINE; LEFLUNOMIDE; PLACEBO; TERIFLUNOMIDE;

ALLERGIC ENCEPHALOMYELITIS; ALOPECIA; BLOOD PRESSURE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; HAIR LOSS; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INCIDENCE; INFECTION; LIVER INJURY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84890189341     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313492810     Document Type: Article

References (51)

1. Bar-Or A. Freedman M. Kremenchutzky M. Menguy-Vacheron F. Bauer D. Jodl S. et al. (2012) Effect of teriflunomide on immune responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis: results from the TERIVA study. Mult Scler 18: 279–508 P925.
2. Comi G. Benzerdjeb H. Wang L. Truffinet P. O'Connor P. (2012) Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Mult Scler 18: 279–508 P439.
3. Comi G. O'Connor P. Wolinsky J. Confavreux C. Kappos L. Olsson T. et al. (2011) Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow-up. Mult Scler 17: S182.
4. Confavreux C. Li D. Freedman M. Truffinet P. Benzerdjeb H. Wang D. et al. (2012) Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 18: 1278–1289.
5. Confavreux C. O'Connor P. Freedman M. Benzerdjeb H. Wang D. Bar-Or A. (2011) Long-term safety and tolerability of teriflunomide in multiple sclerosis: 9-year follow-up of a phase II study. Mult Scler 17: S409.
6. EMA (2006) Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis. London: European Medicines Agency. [Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003485.pdf; accessed January 2013]
7. Freedman M. Cheng S. Truffinet P. Wamil B. Confavreux C. Comi G. et al. (2012 a) TERACLES study design: teriflunomide as adjunctive therapy with interferon-beta in patients with relapsing multiple sclerosis. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May–2 June 2012, San Diego, CA, USA, P9.
8. Freedman M. Confavreux C. Comi G. Kappos L. Olsson T. Miller A. et al. (2012 b) Hair thinning associated with teriflunomide therapy is manageable. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May–2 June 2012, San Diego, CA, USA, P7.
9. Freedman M. Delhay J. Benamor M. (2012 c) Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May–2 June 2012, San Diego, CA, USA, P8.
10. Freedman M. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. et al. (2012 d) Teriflunomide increases the proportion of patients free from disease activity in the TEMSO phase III study. Neurology 78: PD5.007.
11. Freedman M. Wolinsky J. Wamil B. Confavreux C. Comi G. Kappos L. et al. (2011) Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis. Int J MS Care 13: 17.
12. Freedman M. Wolinsky J. Wamil B. Confavreux C. Comi G. Kappos L. et al. (2012 e) Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology 78: 1877–1885.
13. Genzyme Corporation (2012) Aubagio Prescribing Information. Cambridge, MA: Genzyme Corporation.
14. Giovannoni G. Comi G. Cook S. Rammohan K. Rieckmann P. Soelberg Sorensen P. et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416–426.
15. Giovannoni G. Cook S. Rammohan K. Rieckmann P. Sorensen P. Vermersch P. et al. (2011) Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 10: 329–337.
16. Gold R. Wolinsky J. (2011) Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 124: 75–84.
17. Havrdova E. Galetta S. Hutchinson M. Stefoski D. Bates D. Polman C. et al. (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing–remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 8: 254–260.
18. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.
19. Jacobs L. Cookfair D. Rudick R. Herndon R. Richert J. Salazar A. et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285–294.
20. Jennum P. Wanscher B. Frederiksen J. Kjellberg J. (2012) The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur Neuropsychopharmacol 22: 36–43.
21. Johnson K. (1996) Management of relapsing / remitting multiple sclerosis with copolymer 1 (Copaxone). Mult Scler 1: 325–326.
22. Jung Henson L. Stüve O. Kieseier B. Benamor M. Benzerdjeb H. (2013) Pregnancy outcomes from the teriflunomide clinical development program: retrospective analysis of the teriflunomide clinical trial database. Neurology 80: 1001–112005, S30.005.
23. Kappos L. Radue E. O'Connor P. Polman C. Hohlfeld R. Calabresi P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
24. Lad S. Chapman C. Vaninetti M. Steinman L. Green A. Boakye M. (2010) Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology 35: 93–99.
25. Li L. Liu J. Ringheim G. Delohery T. Jones C. (2011) The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells. Mult Scler 17: S422.
26. Limsakun T. Menguy-Vacheron F. (2010 a) Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Neurology 74: P05.032.
27. Limsakun T. Menguy-Vacheron F. (2010 b) Effects of cholestyramine on the elimination of teriflunomide in healthy male volunteers. Mult Scler 16: P11.
28. Loma I. Heyman R. (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9: 409–416.
29. McDonald W. Compston A. Edan G. Goodkin D. Hartung H. Lublin F. et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127.
30. Merrill J. Hanak S. Pu S. Liang J. Dang C. Iglesias-Bregna D. et al. (2009) Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 256: 89–103.
31. Miller A. Lublin F. O'Connor P. Tanio C. Dive-Pouletty C. (2012 a) Impact of relapses with sequelae on disability, health-related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis (RMS) using data from TEMSO, a pivotal phase III teriflunomide trial. Neurology 78: P07.082.
32. Miller A. Lublin F. O'Connor P. Wolinsky J. Comi G. Kappos L. et al. (2012 b) Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology 78: S30.003.
33. Miller A. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. et al. (2011) Clinical and MRI outcomes from a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses. In American Academy of Neurology 63rd Annual Meeting, 9–16 April 2011, Honolulu, HI, S41.002.
34. Miller A. O'Connor P. Wolinsky J. Confavreux C. Kappos L. Olsson T. et al. (2012 c) Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler 18: 1625–1632.
35. Miller A. Turpault S. Menguy-Vacheron F. (2012 d) Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. In Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May–2 June 2012, San Diego, CA, USA, P10.
36. Miller A. Kappos L. Comi G. Confavreux C. Freedman M. Olsson T. et al. (2013) Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from TOWER, a second pivotal phase 3 placebo-controlled study. Neurology 80: S01.004.
37. Naci H. Fleurence R. Birt J. Duhig A. (2010) Economic burden of multiple sclerosis: a systematic review of the literature. Pharmaco Economics 28: 363–379.
38. O'Connor P. Li D. Freedman M. Bar-Or A. Rice G. Confavreux C. et al. (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894–900.
39. O'Connor P. Lublin F. Wolinsky J. Comi G. Kappos L. Freedman M. et al. (2011 a) Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Mult Scler 17(Suppl. 17): S95, P250.
40. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. Olsson T. et al. (2011 b) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365: 1293–1303.
41. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. Olsson T. et al. (2011 c) Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomisation. Mult Scler 17(Suppl. 17): S414, P924.
42. Ogu C. Maxa J. (2000) Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 13: 421–423.
43. Papadopoulou A. Kappos L. Sprenger T. (2012) Teriflunomide for oral therapy in multiple sclerosis. Expert Rev Clin Pharmacol 5: 617–628.
44. Paty D. Li D. (1993) Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS / MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43: 662–667.
45. Petty M. Lee L. Liang J. Ying X. Torino M. Oliver J. et al. (2010) Teriflunomide treatment reduces infiltration of macrophages, T cells and B cells and increases survival of oligodendrocytes in the spinal cord of the Dark Agouti rat model of experimental allergic encephalomyelitis. Neurology 74: A415.
46. PRISMS (1998) Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing / remitting multiple sclerosis. Lancet 352: 1498–1504.
47. Ringheim G. Lee L. Laws-Ricker L. Delohery T. Colletti N. Soos T. et al. (2011) Teriflunomide attentuates immunopathological changes in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Mult Scler 17: S187, P448.
48. sanofi-aventis. (2012) Arava Prescribing Information. US LLC. 2012. Bridgewater, NJ: sanofi-aventis.
49. Vermersch P. Czlonkowska A. Grimaldi L. Confavreux C. Comi G. Kappos L. et al. (2012) Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. J Neurol 259(Suppl. 1): 1–236.
50. Wang L. van Horn R. Turpault S. Zeng Z. (2011) Metabolism comparison between leflunomide and teriflunomide in humans. Eur J Neurol 18(Suppl. 2): 268.
51. Warnke C. Meyer z.u. Horste G. Hartung H. Stuve O. Kieseier B. (2009) Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 5: 333–340.